Báo cáo khoa học: Biological role of bacterial inclusion bodies: a model for amyloid aggregation potx

MINIREVIEW Biological role of bacterial inclusion bodies: a model for amyloid aggregation Elena Garcı ´ a-Fruito ´ s 1–3, *, Raimon Sabate 1,4, *, Natalia S. de Groot 1,4 , Antonio Villaverde 1–3 and Salvador Ventura 1,4 1 Institute for Biotechnology and Biomedicine, Universitat Auto ` noma de Barcelona, Spain 2 Department of Genetics and Microbiology, Universitat Auto ` noma de Barcelona, Spain 3 CIBER de Bioingenierı ´ a, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain 4 Department of Biochemistry and Molecular Biology, Universitat Auto ` noma de Barcelona, Spain Biotechnology of bacterial inclusion bodies; a historical view Production of recombinant proteins in microorgan- isms, powered in the late 1970s by the identification of restriction enzymes, has provided much fewer products than initially expected [1]. The ready-to-use concept of recombinant DNA technologies has proved to be unre- alistic and has faced severe obstacles associated with the physiology of the host microorganism. This is because the cellular protein factories are usually forced to produce heterologous polypeptides, encoded in a multicopy expression plasmid, over physiological rates Keywords aggregation; amyloid; FTIR; inclusion bodies; protein folding; protein quality; recombinant proteins Correspondence A. Villaverde, Institute for Biotechnology and Biomedicine, Universitat Auto ` noma de Barcelona, Bellaterra, 08193 Barcelona, Spain Fax: +34 93 581 2011 Tel: +34 93 581 2148 E-mail: Antoni.Villaverde@uab.cat S. Ventura, Institute for Biotechnology and Biomedicine, Universitat Auto ` noma de Barcelona, Bellaterra, 08193 Barcelona, Spain Fax: +34 93 581 2011 Tel: +34 93 586 8956 E-mail: salvador.ventura@uab.es *These authors contributed equally to this work (Received 28 January 2011, revised 18 March 2011, accepted 15 April 2011) doi:10.1111/j.1742-4658.2011.08165.x Inclusion bodies are insoluble protein aggregates usually found in recombi- nant bacteria when they are forced to produce heterologous protein species. These particles are formed by polypeptides that cross-interact through sterospecific contacts and that are steadily deposited in either the cell’s cytoplasm or the periplasm. An important fraction of eukaryotic proteins form inclusion bodies in bacteria, which has posed major problems in the development of the biotechnology industry. Over the last decade, the fine dissection of the quality control system in bacteria and the recognition of the amyloid-like architecture of inclusion bodies have provided dramatic insights on the dynamic biology of these aggregates. We discuss here the relevant aspects, in the interface between cell physiology and structural biology, which make inclusion bodies unique models for the study of pro- tein aggregation, amyloid formation and prion biology in a physiologically relevant background. Abbreviations IB, inclusion body; PFD, prion forming domain. FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS 2419 – a combination of facts that tend to saturate the pro- tein synthesis machinery and activate the quality con- trol system. Essentially, protein production processes in bacteria (as well as in other microorganisms) suffer from protein degradation and lack of solubility and, to a minor extent, toxicity exerted by the product on the cells and consequent genetic instability (including plas- mid loss). These events occur in the context of several cell stress responses, which depending on the nature of the host microorganism include triggering of oxidative stress, the unfolded protein response, the heat shock and the stringent response and the activation of the DNA repair SOS system [2]. Traditionally, lack of solubility and the formation of inclusion bodies (IBs), large insoluble clusters enriched by misfolded versions of the recombinant protein spe- cies [3], have been the main obstacle for the smooth consecution of production processes, aimed at high yields of soluble, biologically active species. Believed to be irreversibly formed and containing inactive proteins, how to minimize IB formation in midstream has been a matter of extensive discussion. Essentially, reducing the growth temperature, lowering the transcription rate and co-producing folding modulators selected from the quality control system have been thoroughly explored strategies [4]. Also, at the downstream level, refolding of IB proteins has also been approached [5]. Both mid- stream- and downstream-focused approaches have been successful for an important number of specific proteins but they do not offer generic solutions to the lack of solubility in protein production. Despite the economical relevance of IB formation for both catalysis and biotech industries, IBs have been in general poorly characterized. Consequently, the dis- covery of the reversibility of IB formation [6], the gen- eral acceptance of IBs being formed by functional proteins [7] and the recognition of the amyloid-like architecture of IB proteins [8] have represented dra- matic insights in the biology of these structures that has favoured important advances in the comprehension of their physiological and structural nature. For instance, the conceptual unlinking between solubility and functional quality [9], and the fact that enhanced protein yields result in lower quality protein species [10,11], has permitted IBs to be explored as powerful biocatalysts (the embedded proteins acting as immobi- lized enzymes) [12,13]. On the other hand, the fine and timely analysis of the amyloid architecture of IB proteins [14,15] has led to the use of these underesti- mated bacterial aggregates as intriguing models for the analysis of protein–protein interactions in the context of amyloid and prion diseases. Dynamics of IB formation and biological activity Intracellular electrodense proteinaceous granules had been observed in classical experiments when bacteria Soluble VP1LAC + (1/10) VP1LAC IBs Soluble VP1LAC + (1/10) TSP IBs Soluble VP1LAC + (1/10) SPC-PI3DT IBs Soluble VP1LAC + (1/10) HIVP IBs Soluble LACZ Soluble LACZ + (1/10) VP1LAC IBs B A C Fig. 1. A nucleation ⁄ polymerization self- assembly process drives the formation of IBs in bacteria. (A) In vivo formation of IBs in recombinant bacteria. Aggregation-prone versions of the recombinant protein (green) slowly form seeding nuclei by cross-molecu- lar stereospecific interactions. These proto- aggregates recruit further copies of the tar- get protein, in a process compatible with first-order kinetics. This promotes a fast mass growth of IBs. Non-homologous cellu- lar or recombinant proteins (red, black) are excluded from these seeding events. (B) Kinetics of aggregation monitored by time- dependent increase of turbidity at 350 nm using soluble VP1LAC and LACZ incubated with different IBs (figure modified from [8]). (C) Kinetics of Ab42 peptide seeding moni- tored through thioflavin-T fluorescence emis- sion (figure taken from [58]). All figures have been reproduced with permission. Biological role of bacterial inclusion bodies E. Garcı ´ a-Fruito ´ s et al. 2420 FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS were cultured in the presence of non-natural amino acids. This observation, which indicated the transient nature of protein aggregates formed by conformation- ally aberrant proteins, was more recently repeated with bacterial IBs [6], so far believed to be irreversible pro- tein clusters averse to in vivo protein refolding [16]. 200 nm 50 nm 200 nm 500 nm 0.2 0.4 0.6 CR free CR + CR + CR + HET-s (001–289) HET-s (157–289) Absorbance HET-s (218–289) 375 475 575 675 0.0 Wavelength (nm) 0.3 CR + CR + HET-s (001–289) 0.8 1.0 1600162016401660 1680 1700 0.0 0.2 0.4 0.6 Absorbance 0.001 1628 cm –1 Inter β-sheet band 1600 1620 1640 1660 1680 1700 –0.005 –0.003 –0.001 Wavenumber (cm –1 )Wavenumber (cm –1 ) Second derivative 50 nm 375 475 575 675 –0.1 0.0 0.1 0.2 CR + Wavelength (nm) Differential absorbance HET-s (157–289) HET-s (218–289) ≈ 540 nm 50 nm 15 190 200 210 220 230 240 250 –10 –5 0 5 10 Wavelength (nm) θ (mdeg·cm 2 ·dmol –1 ) 1.0 0 50 100 150 200 0.0 0.2 0.4 0.6 0.8 1.0 Without IBs HET-s Full length IBs HET-s (157–289) IBs HET-s PFD IBs [HET-s PFD] = 10 μM Time (min) Aggregated fraction A C E G I J L M K F D H B Fig. 2. Presence of amyloid-like structures in the IBs formed by the prion protein HET-s from P. anserina. (A) HET-s PFD IBs from E. coli observed by cryo-electron microscopy in intact E. coli cells. (B) Transmission electron micrograph of negatively stained purified HET-s PFD IBs. (C), (D) HET-s IB structure before (C) and after (D) 30 min of proteinase K digestion monitored by transmission electron microscopy, showing the apparition of fibrillar structures. (E)–(H) Congo Red (CR) binding to different HET-s IBs monitored by UV ⁄ vis spectroscopy and staining and birefringence under cross-polarized light using an optical microscope: (E), (F) CR spectral changes in the presence of different HET-s IBs; (E) changes in k max and intensity in CR spectra in the presence of HET-s IBs; (F) difference absorbance spectra of CR in the pres- ence and absence of IBs showing in all cases the characteristic amyloid band at  540 nm; (G) HET-s PFD IBs stained with CR and observed at 40· magnification and (H) the same field observed between crossed polarizers displaying the green birefringence characteristic of amyloid structures. (I) 13 C– 13 C solid-state NMR correlation spectrum (proton-driven spin-diffusion with a mixing time of 50 ms) of purified HET-s PFD IBs (blue) compared with a spectrum of in vitro HET-s PFD amyloid fibrils (red) recorded under identical conditions. All the signals assigned for the purified fibrils were also observed in the spectrum of the IBs. The insets demonstrate that no significant changes in the chemical shifts appear and that the linewidths of the two samples are virtually identical. The individual spectra were recorded at a 1H fre- quency of 600 MHz (static field B 0 = 14.9 T), 10 kHz magic angle spinning. (J)–(L) Secondary structure of HET-s PFD IBs: (J) CD spectra, and (K), (L) FTIR absorbance and second derivative spectra in the amide I region of HET-s PFD spectra showing the characteristic spectral bands of b-sheet conformations. (M) Seeding-dependent maturation of HET-s PFD amyloid growth. The aggregation reaction was seeded with HET-s full length, HET-s (157–289), HET-s PFD, Ab40 or Ab42 IBs. The fibrillar fraction of HET-s PFD is represented as a function of time. The formation of HET-s PFD amyloid fibrils is accelerated only in the presence of HET-s IBs. (A), (B) and (I) adapted, with permission, from [60]; (C)–(H) and (J)–(M) adapted, with permission, from [15]. E. Garcı ´ a-Fruito ´ s et al. Biological role of bacterial inclusion bodies FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS 2421 This is indicative of cellular activities acting on these protein aggregates, including release to the soluble cell fraction but also proteolytic events [6,17,18] that might promote degradation of IB proteins in situ [19]. In addition, for protein species that are found in both sol- uble and insoluble cell fractions, the conformational quality and biological activity of IB embedded proteins evolve in parallel with those of the soluble counter- parts, under different environmental conditions affect- ing folding, such as temperature and chaperone availability [20,21]. Therefore, IB proteins appear not to be excluded from quality control [22], in which a complex network of chaperones and proteases survey the folding status of cellular proteins [23], soluble but also insoluble. In agreement with this concept, the main Escherichia coli chaperone DnaK (a holding agent and a foldase and disaggregase), is almost exclusively found, in IB- producing bacteria, attached at the IB surface, while the foldase GroEL is present within the IB core [24]. DnaK, which participates in the in vivo refolding of bacterial thermal aggregates [25,26], appears to be highly active on bacterial IBs [20,27,28]. In fact, we have recently shown that the chaperone DnaK pro- motes protein extraction from bacterial IBs but that this event is intimately associated with proteolysis [10,11]. This explains the reduction of protein yield eventually observed during co-production of this chap- erone and others [10], as a side effect of this strategy [29] addressed to improve the solubility of recombinant proteins. Interestingly, the specific dependence of the DnaK-mediated stimulation on bacterial chaperones makes this chaperone very useful for co-production in eukaryotic systems [30]. The simultaneous surveillance of soluble and IB pro- tein species by bacterial chaperones and proteases indi- cates the occurrence of similar targets in both protein versions and strongly suggests a highly dynamic transi- tion between the two forms. In fact, aggregation and disaggregation seem to be simultaneous events in actively producing recombinant bacteria [16], while dis- aggregation will be highly favoured in the absence of protein synthesis [6]. Such a bidirectional protein tran- sit between the cells’ virtual fractions (soluble and insoluble [22]) accounts for the unexpected and recently determined abundance of soluble aggregates in recombinant cells [31]. These particles, either globular or fibrillar, might be intermediates in the in ⁄ out IB protein transition, or just members of the conforma- tional spectrum that recombinant proteins can adopt in host bacteria, irrespective of whether they are found in soluble or insoluble cell fractions. Interestingly, increasing evidence supports the presence of biologi- cally active proteins embedded in IBs, indicating that both folded and misfolded polypeptides coexist in these proteinaceous aggregates [32]. Regarding the presence of functional protein in such aggregates, different enzyme-based IBs have been successfully tested as catalysts of different bioprocesses [33]. Galac- tosidases [7,34], reductases [7], oxidases [35], kinases [36], phosphorylases [37] and aldolases [38] are just some examples of the enzymes used in aggregated form to catalyse specific reactions, opening a promising mar- ket in the biotechnological industry [33]. In this con- text, other authors have also described the use of IBs for the intracellular capture of a co-synthesized target enzyme, obtaining IB particles with the enzyme of interest immobilized in their surface [39]. Stereospecific interactions in protein aggregation Chiti and coworkers pointed out that the intrinsic physicochemical properties of an amino acid sequence, such as hydrophobicity, secondary structure propensity and charge, can determine the aggregation behaviour of a given polypeptide [40,41]. Many examples support the correlation between protein aggregation tendency and amino acid sequence, and it is also possible to identify the aggregation-prone regions of polypeptides using software such as aggrescan [42] or tango [43]. Protein aggregation can be understood as an anoma- lous type of protein–protein interaction. As for native interactions, the attainment of ordered aggregated structures requires the establishment of stereospecific intermolecular contacts. Accordingly, it has been observed that both bacterial [8] and mammalian pro- tein aggregates are formed through a conserved, selec- tive and sequence-specific process. Specificity during protein aggregation is best exemplified by the nucle- ation-driven polymerization of proteins into amyloid aggregates [44], a mechanism reminiscent of that occurring in crystallization processes [45]. Mature amy- loid fibrils possess the faculty to accelerate the forma- tion of new fibrils by acting as a nucleus that seeds the growth of fibrillar structures [46]. However, molecular recognition between aggregated and soluble proteins only occurs when they share a high sequence similar- ity. The requirement for stereospecific interactions during protein aggregation would explain why disease- linked amyloid deposits are composed almost exclu- sively of the pathogenic protein [47] and bacterial IBs are highly enriched in the target recombinant protein [22]. The distribution of side chains in the sequence, such as occurs in protein folding, plays a pivotal role in determining the conformational properties of the Biological role of bacterial inclusion bodies E. Garcı ´ a-Fruito ´ s et al. 2422 FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS aggregated state and the way in which this supramolec- ular ensemble is reached from the initial soluble state. This control is so exquisite that a protein and its backward version (a protein with exactly the same succession of side chains but with a reverted backbone) do not cross seed each other and form aggregates dis- playing different conformational and functional prop- erties [48]. However, apart from the primary sequence, the particular structural and thermodynamic properties of proteins modulate their deposition in physiologically relevant conditions, making it difficult to predict the effective aggregation propensities of polypeptides in cellular environments. Protein aggregation into amyloid structures Protein aggregation can occur from multiple structural conformations such as intrinsically disordered polypep- tides, oligomeric species or globular proteins [47,49]. The macromolecular assemblies formed by these pro- teins are all sustained by intermolecular interactions but their arrangement and specificity define the degree of order in the structure of the final aggregate. The energy landscape of protein aggregation is rough and complex, comprising both highly energetic amorphous deposits and well-ordered amyloid fibrils of lower energy than the native structure of the protein [50,51]. Amorphous aggregates can be formed rapidly by sim- ple precipitation of the protein, whereas ordered fibril- lation requires specific intermolecular contacts, the formation of which is strongly influenced by the pro- tein local environment [47,52]. The number of identified amyloid-forming proteins increases each year. These fibrillar structures were initially discovered in human tissues of patients suffering from amyloidoses such as Alzheimer’s or Parkinson’s diseases. The study of these deposits has shown that mature fibrils can be less cytotoxic than the intermediary forms in the aggregation pathway suggesting that the amyloid structure might play in fact a protective function [47,53]. Importantly, amy- loid conformations are not only associated with path- ological conditions but are also exploited by Nature to execute important regulatory, structural and genetic functions [54,55]. In fact, the ability to form amyloid assemblies has been suggested to be a gen- eric protein property [47,56] and, as we shall see in the next sections, a conformation accessible to struc- turally and sequentially unrelated proteins upon recombinant expression [51]. Despite their diverse origin, all amyloid structures share common morphological characteristics: straight unbranched fibrils 7–12 nm in diameter made up of two to six protofilaments 2–5 nm in diameter with a cross-b-sheet spine [47,57] in which each polypeptide chain is structured into b-strands and each b-strand is arranged perpendicular to the long axis of the fibril. This arrangement allows a tightly packed quaternary structure sustained mainly by generic hydrogen bonds and hydrophobic contacts [58], explaining why, in spite of the high sequential specificity driving amyloid for- mation pathways, any sequence able to be accommo- dated in a b-sheet conformation can, potentially, reach the amyloid state [51,56]. Amyloid-like properties of bacterial IBs The architecture and mechanisms of IB formation in bacteria have remained unexplored for years. However, important insights in this field have lately emerged. Although IBs were conventionally described as disor- dered aggregates being formed by non-specific interac- tions of exposed hydrophobic surfaces, an increasing amount of evidence is showing that in fact IBs are highly ordered protein deposits formed through a process simi- lar to that observed during amyloid deposition [8,14]. Just as occurs for amyloids, IB formation is driven by intermolecular interactions occurring through homolo- gous protein patches in a nucleation-dependent manner (Figure 1) [8]. On the one hand, a study published by Carrio ´ and coworkers demonstrates that target recombi- nant protein aggregation in vitro is a tightly regulated phenomenon, and recombinant proteins preferentially associate with themselves rather than with other pro- teins in the environment in a dose-dependent way [8]. On the other hand, an in vivo study performed using fluorescence resonance energy transfer shows that, when co-producing two different recombinant proteins in the complex bacterial cytoplasmic environment, the distri- bution of the two proteins in the formed IBs is also tightly regulated through specific contacts, each protein being specifically localized in a different region of the aggregate depending on its sequence. Therefore, it is not surprising that, in spite of the IBs’ amorphous macro- scopic appearance, recently different groups have con- verged to demonstrate unequivocally the effective existence of amyloid-like structures inside bacterial aggregates [14,59]. Accordingly, relative to the native conformation, proteins embedded in IBs appear to be enriched in b-sheet secondary structure elements dis- playing the minimum at 217 nm characteristic of this conformation in the far-UV circular dichroism spectra (which can be displaced slightly to higher wavelengths due to the stacking of aromatic residues) as well as a band at 1620–1630 cm )1 in the infrared spectra, typical E. Garcı ´ a-Fruito ´ s et al. Biological role of bacterial inclusion bodies FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS 2423 of the tightly bound intermolecular b-strands in amyloid structures [8,15,59–61], and X-ray diffraction patterns with meridional (4.8 A ˚ ) and equatorial (10–11 A ˚ ) reflec- tions compatible with the presence of a cross- b structure [59]. In addition, amyloid-specific dyes like Congo Red or thioflavin-T and S bind to bacterial IBs with similar affinity to the affinity they exhibit for amyloid structures [8,15,59–61], confirming a high degree of conforma- tional similarity between the two types of aggregates. As in amyloid fibrils, IBs display regions with high resis- tance against proteolytic attack, probably correspond- ing to a preferentially protected b-sheet core. The presence of fibrillar structures with amyloid-like mor- phology in IBs has been observed directly or after con- trolled proteolytic digestion by transmission electronic microscopy, cryo-electron microscopy [59,62] and atomic force microscopy [15,60,61]. In addition, IBs formed by amyloid proteins display the capacity to seed and accelerate in a highly specific manner the formation of amyloid structures by their soluble and monomeric forms [15,60–62] (see Figure 2). Aggregated structures are non-crystalline and insolu- ble and are therefore not amenable to X-ray crystallog- raphy and solution NMR, the classical tools of structural biology, making it difficult to characterize the fine structure of these assemblies at the residue level, even when they display a high degree of internal order [63]. Quenched hydrogen ⁄ deuterium exchange with solution NMR allows the identification of sol- vent-protected backbone amide protons involved in hydrogen bonds. Interestingly enough, three recent studies using this approach to study the IBs formed by different protein models convincingly demonstrate the presence of sequence-specific motifs displaying protection compatible with a cross-b conformation [59,61,62]. High resolution information on the confor- mation of proteins in the aggregated state can be obtained by solid-state NMR, a technique that has allowed amyloid fibrils to be modelled at atomic reso- lution [64]. Two recent works have exploited solid-state NMR to address the fine structure of the IBs formed by two amyloidogenic proteins, the HET-s prion form- ing domain (PFD) of the fungus Podospora anserina and the Alzheimer’s amyloid b peptide (Ab). The com- parison between the signals of the in vitro formed amy- loid fibrils and the corresponding IBs indicates the existence of regions with highly similar structural dis- position in these aggregates, in particular in the case of HET-s PFD where the NMR signals of the two types of aggregates overlap significantly [61,62,65]. Overall, it appears that the formation of amyloid-like assem- blies is an omnipresent process in both eukaryotic and prokaryotic cells. Infectious conformations in bacterial IBs Prions represent a particular subclass of amyloids in which the aggregation process becomes self-perpetuat- ing in vivo and thus infectious [14]. The possibility that the bacterial IBs formed by recombinant prion pro- teins could display infectious properties has important implications. On the one hand, bacteria might become a simple and tunable in vivo system to study the deter- minants of prion formation. On the other hand, bacte- rial IBs would be an ideal system for the production of significant amounts of infectious proteins ready to use for cell biology studies, without the requirement of the highly inefficient in vitro unfolding ⁄ refolding and controlled aggregation procedures necessary to obtain proteins in transmissible conformations. Therefore, the infectious capacity of prion proteins deposited in bac- teria during recombinant production is receiving increasing attention. Meier and co-workers have tested the ability of HET-s PFD IBs purified from E. coli to infect strains of its natural host, P. anserina, using dif- ferent protein transfection methods [62]. Strains trans- fected with HET-s PFD IBs acquired the [Het-s] prion phenotype at a frequency comparable with that obtained with HET-s PFD infectious fibrils assembled in vitro, confirming that bacterial HET-s PFD IBs dis- play a high prion infectivity [62]. In contrast, the IBs of a heterologous amyloid protein were not infectious. The yeast prion protein Sup35 has also been shown recently to access an infectious structure when pro- duced in E. coli cells [66]. These two independent observations confirm that the content of the bacterial cytoplasm can support the formation of infectious con- formations and suggest that bacterial aggregation might become a generic model system to understand prion biology. Bacteria as model systems to study protein aggregation In addition to being the default protein production cel- lular factories, bacterial cells are valuable systems to understand the integration of metabolic, regulatory and structural features in living cells. The similarities between bacterial aggregates and the deposits formed in higher organisms in pathological processes like amy- loid fibrils, nuclear inclusions and aggresomes [67,68] provide a unique opportunity to dissect the molecular pathways triggering these disorders in a simple, yet physiologically relevant, organism. Accordingly, E. coli has been used to study the link between protein aggre- gation and ageing [69], the role of the highly conserved Biological role of bacterial inclusion bodies E. Garcı ´ a-Fruito ´ s et al. 2424 FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS protein quality machinery on the conformational prop- erties of aggregated states [20,67], the effect of the pro- tein sequence on in vivo aggregation kinetics [41], the influence of extrinsic factors like temperature on pro- tein aggregation properties [21,70] or the control of polypeptide solubility in biological environments by the thermodynamic [71] and kinetic stability of pro- teins [72]. In addition, the possibility of labelling aggregation-prone proteins with natural [41] or artifi- cial fluorophores [73] allows in vivo deposition path- ways to be tracked in real time and compounds able to block the self-assembly process to be identified [74]. Finally, bacteria provide a means to trap and study the highly toxic, unstable and transient intermediates in the fibrillation reaction, illuminating one of the more obscure but crucial steps in amyloid fibril forma- tion [61]. Acknowledgements We appreciate the financial support from MICINN (BFU2010-17450 and BFU2010-14901), AGAUR (2009SGR-00108 and 2009SGR-00760) and CIBER de Bioingenierı ´ a, Biomateriales y Nanomedicina (CIBER- BBN, Spain), an initiative funded by the VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, Con- solider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. A.V. and S.V. have been distinguished with an ICREA Academia award. References 1 Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E & Villaverde A (2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 8, 17–24. 2 Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodri- guez-Carmona E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C et al. (2008) Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 7, 11–28. 3 Villaverde A & Carrio ´ MM (2003) Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnol Lett 25, 1385–1395. 4 Sorensen HP & Mortensen KK (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115, 113–128. 5 Vallejo LF & Rinas U (2004) Strategies for the recovery of active proteins through refolding of bacterial inclu- sion body proteins. Microb Cell Fact 3, 11–22. 6 Carrio MM & Villaverde A (2001) Protein aggregation as bacterial inclusion bodies is reversible. FEBS Lett 489, 29–33. 7 Garcı ´ a-Fruito ´ s E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A, Ventura S & Villaverde A (2005) Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent pro- teins. Microb Cell Fact 4, 27–32. 8 Carrio ´ M, Gonzalez-Montalban N, Vera A, Villaverde A & Ventura S (2005) Amyloid-like properties of bacte- rial inclusion bodies. J Mol Biol 347, 1025–1037. 9 Gonzalez-Montalban N, Garcı ´ a-Fruito ´ s E & Villaverde A (2007) Recombinant protein solubility – does more mean better? Nat Biotechnol 25, 718–720. 10 Garcı ´ a-Fruito ´ s E, Martinez-Alonso M, Gonzalez-Mon- talban N, Valli M, Mattanovich D & Villaverde A (2007) Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol 374, 195–205. 11 Martinez-Alonso M, Garcı ´ a-Fruito ´ s E & Villaverde A (2008) Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng 101, 1353–1358. 12 Garcı ´ a-Fruito ´ s E (2010) Inclusion bodies: a new con- cept. Microb Cell Fact 9, 80–82. 13 Martinez-Alonso M, Gonzalez-Montalban N, Garcı ´ a- Fruito ´ s E & Villaverde A (2009) Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact 8, 4–8. 14 de Groot NS, Sabate R & Ventura S (2009) Amyloids in bacterial inclusion bodies. Trends Biochem Sci 34, 408–416. 15 Sabate R, Espargaro A, Saupe SJ & Ventura S (2009) Characterization of the amyloid bacterial inclusion bodies of the HET-s fungal prion. Microb Cell Fact 8, 56–65. 16 Carrio ´ MM & Villaverde A (2002) Construction and deconstruction of bacterial inclusion bodies. J Biotech- nol 96, 3–12. 17 Jurgen B, Breitenstein A, Urlacher V, Buttner K, Lin H, Hecker M, Schweder T & Neubauer P (2010) Qual- ity control of inclusion bodies in Escherichia coli. Mic- rob Cell Fact 9, 41–53. 18 Vera A, Aris A, Carrio ´ M, Gonzalez-Montalban N & Villaverde A (2005) Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. J Biotechnol 119, 163–171. 19 Carbonell X & Villaverde A (2002) Protein aggregated into bacterial inclusion bodies does not result in protec- tion from proteolytic digestion. Biotechnology Lett 24, 1939–1944. 20 Martinez-Alonso M, Vera A & Villaverde A (2007) Role of the chaperone DnaK in protein solubility and E. Garcı ´ a-Fruito ´ s et al. Biological role of bacterial inclusion bodies FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS 2425 conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett 273, 187–195. 21 Vera A, Gonzalez-Montalban N, Aris A & Villaverde A (2007) The conformational quality of insoluble recombi- nant proteins is enhanced at low growth temperatures. Biotechnol Bioeng 96, 1101–1106. 22 Ventura S & Villaverde A (2006) Protein quality in bacterial inclusion bodies. Trends Biotechnol 24, 179– 185. 23 Bukau B, Weissman J & Horwich A (2006) Molecular chaperones and protein quality control. Cell 125, 443–451. 24 Carrio ´ MM & Villaverde A (2005) Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol 187, 3599–3601. 25 Schlieker C, Tews I, Bukau B & Mogk A (2004) Solubi- lization of aggregated proteins by ClpB ⁄ DnaK relies on the continuous extraction of unfolded polypeptides. FEBS Lett 578, 351–356. 26 Weibezahn J, Bukau B & Mogk A (2004) Unscrambling an egg: protein disaggregation by AAA+ proteins. Microb Cell Fact 3, 1–12. 27 Gonzalez-Montalban N, Garcı ´ a-Fruito ´ s E, Ventura S, Aris A & Villaverde A (2006) The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body- forming cells. Microb Cell Fact 5, 26–34. 28 Gonzalez-Montalban N, Natalello A, Garcı ´ a-Fruito ´ sE, Villaverde A & Doglia SM (2008) In situ protein folding and activation in bacterial inclusion bodies. Biotechnol Bioeng 100, 797–802. 29 Martinez-Alonso M, Garcı ´ a-Fruito ´ s E, Ferrer-Miralles N, Rinas U & Villaverde A (2010) Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact 9, 64–69. 30 Martinez-Alonso M, Gomez-Sebastian S, Escribano JM, Saiz JC, Ferrer-Miralles N & Villaverde A (2009) DnaK ⁄ DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol 86, 633–639. 31 de Marco A & Schroedel A (2005) Characterization of the aggregates formed during recombinant protein expression in bacteria. BMC Biochem 6, 10–20. 32 Hamodrakas SJ (2011) Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies. FEBS J 278, 2428–2435. 33 Ferrer-Miralles N, Martinez-Alonso M, Villaverde A & Garcı ´ a-Fruito ´ s E (2010) Inclusion Bodies: A New Con- cept of Biocatalysts . Protein Aggregation. Nova Science Publishers, New York. 34 Garcı ´ a-Fruito ´ s E, Aris A & Villaverde A (2007) Locali- zation of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol 73, 289–294. 35 Nahalka J, Dib I & Nidetzky B (2008) Encapsulation of Trigonopsis variabilis D-amino acid oxidase and fast comparison of the operational stabilities of free and immobilized preparations of the enzyme. Biotechnol Bioeng 99, 251–260. 36 Nahalka J & Patoprsty V (2009) Enzymatic synthesis of sialylation substrates powered by a novel polyphosphate kinase (PPK3). Org Biomol Chem 7, 1778–1780. 37 Nahalka J (2008) Physiological aggregation of maltod- extrin phosphorylase from Pyrococcus furiosus and its application in a process of batch starch degradation to alpha-D-glucose-1-phosphate. J Ind Microbiol Biotech- nol 35, 219–223. 38 Nahalka J, Vikartovska A & Hrabarova E (2008) A crosslinked inclusion body process for sialic acid synthe- sis. J Biotechnol 134, 146–153. 39 Steinmann B, Christmann A, Heiseler T, Fritz J & Kol- mar H (2010) In vivo enzyme immobilization by inclu- sion body display. Appl Environ Microbiol 76 , 5563– 5569. 40 Chiti F, Stefani M, Taddei N, Ramponi G & Dobson CM (2003) Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805–808. 41 de Groot NS, Aviles FX, Vendrell J & Ventura S (2006) Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer’s peptide. Side-chain properties correlate with aggregation propensities. FEBS J 273, 658–668. 42 Conchillo-Sole O, de Groot NS, Aviles FX, Vendrell J, Daura X & Ventura S (2007) AGGRESCAN: a server for the prediction and evaluation of ‘hot spots’ of aggregation in polypeptides. BMC Bioinformatics 8, 65–81. 43 Fernandez-Escamilla AM, Rousseau F, Schymkowitz J & Serrano L (2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22, 1302–1306. 44 Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV & Dobson CM (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13, 1933–1938. 45 Harper JD, Lieber CM & Lansbury PT (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer’s disease amyloid- beta protein. Chem Biol 4 , 951–959. 46 Jarrett JT & Lansbury PT (1993) Seeding ‘one-dimen- sional crystallization’ of amyloid: a pathogenic mecha- nism in Alzheimer’s disease and scrapie? Cell 73, 1055– 1058. 47 Chiti F & Dobson CM (2006) Protein misfolding, func- tional amyloid, and human disease. Annu Rev Biochem 75, 333–366. 48 Sabate R, Espargaro A, de Groot NS, Valle-Delgado JJ, Fernandez-Busquets X & Ventura S (2010) The role Biological role of bacterial inclusion bodies E. Garcı ´ a-Fruito ´ s et al. 2426 FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS of protein sequence and amino acid composition in amyloid formation: scrambling and backward reading of IAPP amyloid fibrils. J Mol Biol 404, 337–352. 49 Uversky VN & Fink AL (2004) Conformational con- straints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 1698 , 131–153. 50 Jahn TR & Radford SE (2008) Folding versus aggrega- tion: polypeptide conformations on competing path- ways. Arch Biochem Biophys 469, 100–117. 51 Gatti-Lafranconi P, Natalello A, Ami D, Doglia SM & Lotti M (2011) Concepts and tools to exploit the poten- tial of bacterial inclusion bodies in protein science and biotechnology. FEBS J 278, 2408–2418. 52 Ecroyd H & Carver JA (2008) Unraveling the mysteries of protein folding and misfolding. IUBMB Life 60, 769–774. 53 Merlini G & Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349, 583–596. 54 Fowler DM, Koulov AV, Balch WE & Kelly JW (2007) Functional amyloid – from bacteria to humans. Trends Biochem Sci 32, 217–224. 55 Sabate R, de Groot NS & Ventura S (2010) Protein folding and aggregation in bacteria. Cell Mol Life Sci 67, 2695–2715. 56 Greenwald J & Riek R (2010) Biology of amyloid: structure, function, and regulation. Structure 18, 1244– 1260. 57 Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB & Fraser PE (2000) The protofilament substructure of amyloid fibrils. J Mol Biol 300, 1033–1039. 58 Nelson R & Eisenberg D (2006) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16, 260–265. 59 Wang L, Maji SK, Sawaya MR, Eisenberg D & Riek R (2008) Bacterial inclusion bodies contain amyloid-like structure. PLoS Biol 6, e195. 60 Morell M, Bravo R, Espargaro A, Sisquella X, Aviles FX, Fernandez-Busquets X & Ventura S (2008) Inclu- sion bodies: specificity in their aggregation process and amyloid-like structure. Biochim Biophys Acta 1783, 1815–1825. 61 Dasari M, Espargaro A, Sabate R, Lo ´ pez del Amo J, Fink U, Grelle G, Bieschke J, Ventura S & Reif B (2011) Bacterial inclusion bodies of the alzheimer dis- ease beta-amyloid peptides can be employed to study native like aggregation intermediate states. Chem Bio Chem 12, 407–423. 62 Wasmer C, Benkemoun L, Sabate R, Steinmetz MO, Coulary-Salin B, Wang L, Riek R, Saupe SJ & Meier BH (2009) Solid-state NMR spectroscopy reveals that E. coli inclusion bodies of HET-s(218-289) are amy- loids. Angew Chem Int Ed Engl 48, 4858–4860. 63 Thompson LK (2003) Unraveling the secrets of Alzhei- mer’s beta-amyloid fibrils. Proc Natl Acad Sci USA 100, 383–385. 64 Tycko R (2006) Molecular structure of amyloid fibrils: insights from solid-state NMR. Q Rev Biophys 39, 1–55. 65 Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R & Meier BH (2008) Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science 319, 1523–1526. 66 Garrity SJ, Sivanathan V, Dong J, Lindquist S & Hochschild A (2010) Conversion of a yeast prion pro- tein to an infectious form in bacteria. Proc Natl Acad Sci USA 107, 10596–10601. 67 Woulfe J (2008) Nuclear bodies in neurodegenerative disease. Biochim Biophys Acta 1783, 2195–2206. 68 Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10, 524–530. 69 Lindner AB, Madden R, Demarez A, Stewart EJ & Taddei F (2008) Asymmetric segregation of protein aggregates is associated with cellular aging and rejuve- nation. Proc Natl Acad Sci USA 105, 3076–3081. 70 de Groot NS & Ventura S (2006) Effect of temperature on protein quality in bacterial inclusion bodies. FEBS Lett 580, 6471–6476. 71 Espargaro A, Sabate R & Ventura S (2008) Kinetic and thermodynamic stability of bacterial intracellular aggre- gates. FEBS Lett 582, 3669–3673. 72 Castillo V, Espargaro A, Gordo V, Vendrell J & Ven- tura S (2010) Deciphering the role of the thermody- namic and kinetic stabilities of SH3 domains on their aggregation inside bacteria. Proteomics 10, 4172–4185. 73 Ignatova Z & Gierasch LM (2004) Monitoring protein stability and aggregation in vivo by real-time fluorescent labeling. Proc Natl Acad Sci USA 101, 523–528. 74 Kim W, Kim Y, Min J, Kim DJ, Chang YT & Hecht MH (2006) A high-throughput screen for compounds that inhibit aggregation of the Alzheimer’s peptide. ACS Chem Biol 1, 461–469. E. Garcı ´ a-Fruito ´ s et al. Biological role of bacterial inclusion bodies FEBS Journal 278 (2011) 2419–2427 ª 2011 The Authors Journal compilation ª 2011 FEBS 2427 . MINIREVIEW Biological role of bacterial inclusion bodies: a model for amyloid aggregation Elena Garcı ´ a- Fruito ´ s 1–3, *, Raimon Sabate 1,4, *, Natalia S independent observations confirm that the content of the bacterial cytoplasm can support the formation of infectious con- formations and suggest that bacterial aggregation might